IP Journal of Urology, Nephrology and Hepatology Science
Official Publication of Khyati Education And Research Foundation
Official Publication of Khyati Education And Research Foundation
Print ISSN:-XXXX
Online ISSN:-XXXX
Issue
Year 2021
Volume: 4 , Issue: 4
Viewed: 317
Emailed: 0
PDF Downloaded: 293
Full Text PDF Share on Facebook Share on Twitter
Review Article
Author Details :
Volume : 4, Issue : 3, Year : 2021
Article Page : 67-74
Abstract
Gastric cancer is one of the most common gastrointestinal malignancies associated with higher mortality and a high recurrence rate. Early detected gastric cancer can be managed endoscopically or laparoscopically. The management of locally advanced and metastatic gastric cancer is particularly difficult. Conventional chemotherapy is not useful in all patients with advanced disease. In those patients, the only hope of treatment at present is target therapy. Apart from metastatic disease, target therapy is also useful in a patient with chemoresistance gastric cancer and gastric cancer who failed to respond to conventional chemotherapy
Keywords: Gastric cancer, target therapy, HER2, VEGFR, c-MET, mTOR, Claudin, Immunotherapy
How to cite : Pandiaraja J , Role of target therapy in gastric cancer. J Urol Nephrol Hepatol Sci 2021;4(3):67-74
Copyright © 2021 by author(s) and J Urol Nephrol Hepatol Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)
